Chargement en cours...
Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment
BACKGROUND: Docetaxel chemotherapy in prostate cancer has a modest impact on survival. To date, efforts to develop combination therapies have not translated into new treatments. We sought to develop a novel therapeutic strategy to tackle chemoresistant prostate cancer by enhancing the efficacy of do...
Enregistré dans:
| Publié dans: | Br J Cancer |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group UK
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7028732/ https://ncbi.nlm.nih.gov/pubmed/31844184 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0681-5 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|